Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

[Clinical observation of aripiprazole in the treatment of autism].

Xie Q, Tang J, Xu Y, Zeng HL.

Zhongguo Dang Dai Er Ke Za Zhi. 2013 Apr;15(4):294-7. Chinese.

2.

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.

Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL.

Pediatrics. 2009 Dec;124(6):1533-40. doi: 10.1542/peds.2008-3782.

PMID:
19948625
3.

Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.

Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F.

CNS Drugs. 2009;23(6):511-21. doi: 10.2165/00023210-200923060-00005.

PMID:
19480469
4.

Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study.

Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Corey-Lisle PK, Aman MG.

J Child Adolesc Psychopharmacol. 2011 Jun;21(3):229-36. doi: 10.1089/cap.2009.0121.

PMID:
21663425
5.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
6.

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.

Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL.

J Clin Psychiatry. 2011 Sep;72(9):1270-6. doi: 10.4088/JCP.09m05933. Epub 2011 Jul 26.

PMID:
21813076
7.

An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders.

Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY.

J Clin Psychiatry. 2007 Jul;68(7):1088-93.

PMID:
17685747
8.

[A control study of aripiprazole and tiapride treatment for tic disorders in children].

Liu YY, Chen YH, Chen H, Liu ZS.

Zhongguo Dang Dai Er Ke Za Zhi. 2010 Jun;12(6):421-4. Chinese.

9.

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.

Valicenti-McDermott MR, Demb H.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):549-60.

PMID:
17069544
10.

Effectiveness and tolerability of switching to aripiprazole from risperidone in subjects with autism spectrum disorders: a prospective open-label study.

Ishitobi M, Kosaka H, Takahashi T, Yatuga C, Asano M, Tanaka Y, Ueno K, Okazaki R, Omori M, Hiratani M, Tomoda A, Wada Y.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):151-6. doi: 10.1097/WNF.0b013e3182a31ec0.

PMID:
24045605
11.

Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder.

Aman MG, Kasper W, Manos G, Mathew S, Marcus R, Owen R, Mankoski R.

J Child Adolesc Psychopharmacol. 2010 Oct;20(5):415-22. doi: 10.1089/cap.2009.0120.

PMID:
20973712
12.

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial.

Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA.

J Clin Psychiatry. 2009 Apr 21;70(5):756-64. doi: 10.4088/JCP.08m04726.

PMID:
19389329
13.

Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation.

Gibson AP, Crismon ML, Mican LM, Fischer C.

Int Clin Psychopharmacol. 2007 Mar;22(2):101-5.

PMID:
17293710
14.

Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials.

Varni JW, Handen BL, Corey-Lisle PK, Guo Z, Manos G, Ammerman DK, Marcus RN, Owen R, McQuade RD, Carson WH, Mathew S, Mankoski R.

Clin Ther. 2012 Apr;34(4):980-92. doi: 10.1016/j.clinthera.2012.02.023. Epub 2012 Mar 22.

PMID:
22444782
15.

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.

Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ.

J Child Adolesc Psychopharmacol. 2009 Jun;19(3):265-74. doi: 10.1089/cap.2008.093.

16.

Aripiprazole for the treatment of irritability associated with autism.

Farmer CA, Aman MG.

Expert Opin Pharmacother. 2011 Mar;12(4):635-40. doi: 10.1517/14656566.2011.557661. Epub 2011 Feb 6. Review.

17.

Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.

Kwon JS, Jang JH, Kang DH, Yoo SY, Kim YK, Cho SJ; APLUS study group.

Psychiatry Clin Neurosci. 2009 Feb;63(1):73-81. doi: 10.1111/j.1440-1819.2008.01907.x.

18.

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

Mintzer JE, Tune LE, Breder CD, Swanink R, Marcus RN, McQuade RD, Forbes A.

Am J Geriatr Psychiatry. 2007 Nov;15(11):918-31.

PMID:
17974864
19.

A prospective, multicentre, open-label study to evaluate the effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia.

Peuskens J, Bervoets C, Kok F, Delatte B, Touquet G, Gillain B, de Patoul A, Halkin V, Loze JY, Vansteelandt K, Constant E.

Eur Psychiatry. 2012 Oct;27(7):506-12. doi: 10.1016/j.eurpsy.2011.06.008. Epub 2011 Sep 14.

PMID:
21920707
20.

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW.

J Clin Psychiatry. 2002 Sep;63(9):763-71.

PMID:
12363115

Supplemental Content

Support Center